Education
About Us
Working with TipRanks
Follow Us
Ani Pharmaceuticals (ANIP)
:ANIP
ANIP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$52.50 - $70.00
Previous CloseN/A
Volume18.69K
Average Volume (3M)393.83K
Market Cap
$1.46B
Enterprise Value$1.58B
Total Cash (Recent Filing)$41.16M
Total Debt (Recent Filing)$18.09M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 09, 2025EPS Estimate
1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding21,762,646
10 Day Avg. Volume430,623
30 Day Avg. Volume393,833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.20
Price to Cash Flow (P/CF)21.30
P/FCF Ratio16.90
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda28.77
Forecast
1Y Price Target
$85.00Price Target Upside28.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Cortrophin GrowthThe outlook for Cortrophin Gel, with expected significant growth, is underappreciated and is expected to drive multiple expansion.
Generics GrowthGenerics transaction data is trending better than expected, with an estimated 35% year-over-year transaction growth, bolstering the setup for strong revenue in the upcoming quarter.
Regulatory ApprovalThe FDA approved an expanded Iluvien label, adding chronic non-infection uveitis affecting the posterior segment (NIU-PS) to the current DME indication, which came earlier than expected and reflects continued ANI regulatory execution.
Bears Say
Product Traction RisksThere is a risk that Iluvien/Yutiq may take time to gain traction, and the company could fail to drive Cortrophin volumes as expected.
Rare Disease Portfolio ValuationThe stock is trading at a valuation more suitable for a pure generics company, despite significant contributions and growth from the rare disease portfolio.
Seasonality ImpactRare disease segment is experiencing a sequential step-down due to seasonality, which seems appropriately reflected in consensus estimates.
---
Ownership Overview
11.10% Insiders
20.25% Mutual Funds
23.46% Other Institutional Investors
26.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANIP FAQ
What was Ani Pharmaceuticals’s price range in the past 12 months?
Ani Pharmaceuticals lowest stock price was $52.50 and its highest was $70.00 in the past 12 months.
What is Ani Pharmaceuticals’s market cap?
Ani Pharmaceuticals’s market cap is $1.46B.
When is Ani Pharmaceuticals’s upcoming earnings report date?
Ani Pharmaceuticals’s upcoming earnings report date is May 09, 2025 which is in 29 days.
How were Ani Pharmaceuticals’s earnings last quarter?
Ani Pharmaceuticals released its earnings results on Feb 28, 2025. The company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.435 by $0.195.
Is Ani Pharmaceuticals overvalued?
According to Wall Street analysts Ani Pharmaceuticals’s price is currently Undervalued.
Does Ani Pharmaceuticals pay dividends?
Ani Pharmaceuticals does not currently pay dividends.
What is Ani Pharmaceuticals’s EPS estimate?
Ani Pharmaceuticals’s EPS estimate is 1.35.
How many shares outstanding does Ani Pharmaceuticals have?
Ani Pharmaceuticals has 21,762,646 shares outstanding.
What happened to Ani Pharmaceuticals’s price movement after its last earnings report?
Ani Pharmaceuticals reported an EPS of $1.63 in its last earnings report, beating expectations of $1.435. Following the earnings report the stock price went up 13.393%.
Which hedge fund is a major shareholder of Ani Pharmaceuticals?
Currently, no hedge funds are holding shares in ANIP
---
ANI Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.00 (28.77% Upside)
$85.00 (28.77% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 113.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $323.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.55%
12-Months-Change
Fundamentals
Return on Equity
-4.86%
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
Ani Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
---
ANIP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
ANI Pharmaceuticals demonstrated strong performance in 2024, with record results and increased guidance for 2025. The company showed significant growth in its Rare Disease and Generics businesses and completed a strategic acquisition. However, there are challenges related to market access for ILUVIEN and YUTIQ and potential disruptions due to manufacturing transitions. Despite these challenges, the positive momentum and strategic initiatives in place suggest a cautiously optimistic outlook.Read More>---
ANIP Stock 12 Month Forecast
Average Price Target
$85.00
▲(28.77% Upside)
Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Best Analysts Covering ANIP
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+20.45%
reiterated a buy rating 24 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +20.45% per trade.
---